SCHEMBL19607

SCHEMBL19607

CCOc1ccc(Nc2nc3c(-c4ccc(C#N)nc4)nccn3n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.40
KDM4E B2RXH2 3/20 0.39
NFKB1 P19838 1/20 0.39
KDR P35968 2/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
JAK2 O60674 6/20 0.38
JAK3 P52333 5/20 0.38
PTK2 Q05397 4/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
JAK1 P23458 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CHEK1 O14757 1/20 0.37
EIF2AK4 Q9P2K8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15206787 0.90 JAK2 (0.48) KDM4EKDRMAPTGAAJAK2
SCHEMBL19998 0.86 MAPT (0.43) SYKKDM4ENFKB1KDRMAPT
SCHEMBL15207187 0.86 SYK (0.41) SYKKDM4ENFKB1KDRMAPT
SCHEMBL15207896 0.86 CHEK1 (0.40) SYKKDM4EKDRJAK2JAK3
SCHEMBL15207680 0.86 CHEK1 (0.36) SYKKDRJAK2JAK3PTK2
SCHEMBL19101 0.86 TRPA1 (0.44) JAK2JAK3PTK2CHEK1
SCHEMBL31462 0.85 JAK2 (0.49) SYKKDM4ENFKB1KDRJAK2
SCHEMBL21220 0.85 CHEK1 (0.38) SYKKDRJAK2JAK3PTK2
SCHEMBL30790 0.85 JAK2 (0.39) SYKKDM4ENFKB1KDRMAPT
SCHEMBL15207034 0.85 JAK2 (0.40) SYKKDRJAK2JAK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609098-A1 TRIAZOLOPYRAZINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025186-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 SYK 1/4885KDM4E 1552/4885NFKB1 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.